Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN)

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Price, Gregory L ^a   Davis, Keith L ^b   Karve, Sudeep ^b   Pohl, Gerhardt ^a   Walgren, Richard A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICARE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POLYCYTHEMIA VERA; POPULATION RESEARCH; PREVALENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SEX RATIO; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTHEMIA; UNITED STATES; VERY ELDERLY; CANCER REGISTRY; MIDDLE AGED; MORTALITY; MYELOPROLIFERATIVE DISORDERS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MEDICARE; MIDDLE AGED; MORTALITY; MYELOPROLIFERATIVE DISORDERS; PROPORTIONAL HAZARDS MODELS; PUBLIC HEALTH SURVEILLANCE; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84897929701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090299     Document Type: Article

References (30)

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, et al. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117: 5019-5032.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790. (Pubitemid 40570926)
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397. (Pubitemid 40544655)
4. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148. (Pubitemid 40663494)
5. Maynadié M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, et al. (2011) Twenty-five years of epidemiological recording on myeloid malignancies: Data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica 96: 55-61.
6. Leukemia and Lymphoma Society. Disease Information and Support: Myeloproliferative Neoplasms. Available: http://www.lls. org/#/ diseaseinformation/myeloproliferativediseases/.
7. Leukemia and Lymphoma Society. Disease Information and Support: Myeloproliferative Neoplasms, Incidence. Available: http://www.lls.org/#/ diseaseinformation/myeloproliferativediseases/incidence/.
8. Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, et al. (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48: 3257-3266.
9. th ed. International Agency for Research on Cancer. Page 40-41.
10. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ (2013) Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 122: 1881-1886.
11. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J (1999) Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 33: 207-218. (Pubitemid 29196858)
12. Murray J (2005) Myeloproliferative disorders. Clin Med 5: 328-332.
13. Koopmans SM, van Marion AM, Schouten HC (2012) Myeloproliferative neoplasia: a review of clinical criteria and treatment. Neth J Med 70: 159-167.
14. Nattinger AB, McAuliffe TL, Schapira MM (1997) Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 50: 939-45. (Pubitemid 27423524)
15. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(suppl 4): S3-S18.
16. Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, et al. (1994) Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 47:89-93. (Pubitemid 24302276)
17. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A (1999) Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County study, 1976-1995. Am J Hematol 61: 10-15. (Pubitemid 29218171)
18. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81: 159-166. (Pubitemid 43205767)
19. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, et al. (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112: 45-52.
20. Rozman C, Giralt M, Feliu E, Rubio D, Cortés MT (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67: 2658-2663.
21. Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, et al. (2009) Longterm follow-up of 386 consecutive patients with essential thrombocythemia: Safety of cytoreductive therapy. Am J Hematol 84:215-220.
22. Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, et al. (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30: 2995-3001.
23. Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, et al. (2013) Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica 98: 230-238.
24. Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, et al. (2012) Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 30: 2981-2987.
25. Xu Z, Gale RP, Zhang Y, Qin T, Chen H, et al. (2012) Unique features of primary myelofibrosis in Chinese. Blood 119: 2469-2473.
26. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, et al. (2004) Life Expectancy and Prognostic Factors for Survival inpatients with Polycythemia Vera and Essential Thrombocythemia. Am J Med 117: 755-761. (Pubitemid 39482529)
27. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, et al (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22: 756-761. (Pubitemid 351559282)
28. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, et al. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115: 1703-8.
29. Gangat N, Caramazza D, Vaidya R, George G, Begna K, et al. (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392-7.
30. Craig BM, Rollison DE, List AF, Cogle CR (2012) Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev 21: 474-81.